Head of Clinical Development
Team
Rolf Pokorny serves as consulting Head of Early Clinical Drug Development at FundaMental Pharma.
He is an experienced Clinical Pharmacologist with extensive exposure to CNS drug development, both in Big Pharma and as CEO of a 50 bed Clinical Pharmacology Unit. His profound background, combined with recent hands-on experience in early CNS drug development across multiple jurisdictions (US, EU, UK, Australia), is of particular interest to FundaMental Pharma’s mission to bring innovation to patients suffering from Treatment-Resistant Depression. He has 14 years’ experience in early clinical drug development at Big Pharma (Novartis) and served over 15 years as CEO in a 50 bed Clinical Pharmacology Unit (Fortrea).
Rolf has been working since 2013 as an independent consultant with various start-ups in the pharmaceutical field and was responsible for several successful Phase 1 developments including IND filings.
Rolf Pokorny holds a German Diploma (MSc) in electronic engineering, a medical doctor (MD) degree, and a PhD from the University of Erlangen, Germany. He currently authors over 40 peer reviewed scientific articles & reviews and is a co-inventor of granted and pending patents.
Rolf is state licensed as continuing education supervisor in Pharmaceutical Medicine (2002), Swiss Medical Association, Berne, Switzerland, and state licensed Consultant Pharmaceutical Medicine: board certification (2000) Swiss Medical Association, Berne, Switzerland.
